This filtering step identified 14 frequently mutated genes within the patient cohort, mainly bona fide tumor suppressor genes such as APC, ATM, BRCA2, or TP53 and well-known protooncogenes such as GNAS, KRAS, and NRAS. Notably, this analysis revealed tumor characteristic mutational profiles. This evidence concerns the gene KRAS and neoplasm.